A phase 1, open-label, parallel-group clinical trial of KP-415 compare to Concerta, to evaluate the pharmacokinetics of three different co-formulations of the drug to treat attention deficit hyperactivity disorder (ADHD).

Trial Profile

A phase 1, open-label, parallel-group clinical trial of KP-415 compare to Concerta, to evaluate the pharmacokinetics of three different co-formulations of the drug to treat attention deficit hyperactivity disorder (ADHD).

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs KP-415 (Primary) ; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 Aug 2017 New trial record
    • 10 Aug 2017 According to a KemPharm media release, the results will be present at the Canaccord Genuity 37th Annual Growth Conference.
    • 10 Aug 2017 Preliminary results published in the KemPharm Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top